MedTrace Logo

Trial on Safety and Pharmacokinetics of Intravaginal Curcumin

NCT01035580 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2013-11-28

No results posted yet for this study

Summary

The main objective of this study is to determine the maximum tolerable dose and safety of intravaginal curcumin in a normal population of women (women with no evidence of cervical cytological abnormalities by pap testing).

Conditions

  • Uterine Cervical Dysplasia

Interventions

DRUG

Curcumin

Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg

DRUG

curcumin

all patients received the drug

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Lisa Flowers, Medical · Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-04-30
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01035580 on ClinicalTrials.gov